<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">Oseltamivir, an NAI, has been the treatment of choice for influenza infection. The emergence of a resistant virus (after day 1) was detected in 43/1207 (3.56%) oseltamivir-treated influenza A-infected patients, with a higher frequency observed in 1- to 5-year-olds (11.8%) than in children aged &gt;5 years (1.4%), and viral clearance occurred in 8–10 days (
 <xref rid="bb0375" ref-type="bibr">Lina et al., 2018</xref>). The overall incidence of an oseltamivir-resistant virus was 10 of 182 (5.5%) (
 <xref rid="bb0625" ref-type="bibr">Whitley et al., 2001</xref>) and 9 of 50 (18%) (
 <xref rid="bb0295" ref-type="bibr">Kiso et al., 2004</xref>) oseltamivir-treated children. Oseltamivir-resistant influenza appears and becomes dominant during treatment.
</p>
